Creating new methods for attaching drugs to antibodies for better cancer treatment
Official title: Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation
Funded at Glycot Therapeutics, LLC · NIH-11045684 · Data updated 2026-11-12
This study is working on a new way to attach helpful molecules to antibodies, which could make cancer treatments more effective and cause fewer side effects for patients by targeting cancer cells more precisely.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycot Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Ellicott City, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $977,787 |
| NIH project number | 5R44GM153003-02 |
| Project ID | NIH-11045684 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing treatment for cancers that are targeted by antibody-drug conjugates.
✕Less likely to help
Patients with cancers not addressed by antibody-drug conjugates or those not eligible for such therapies may not benefit from this research.
What this research studies
This research focuses on developing a streamlined method for attaching various functional molecules to antibodies, which can enhance their effectiveness in cancer therapy and other applications. By optimizing a one-pot single-zyme glycan-specific conjugation technology, the project aims to create site-specific antibody-drug conjugates (ADCs) that improve the delivery and efficacy of treatments. Patients may benefit from more effective therapies with fewer side effects due to the precise targeting of cancer cells. The approach involves advanced enzymatic techniques to ensure that the antibodies are modified in a way that maximizes their therapeutic potential.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with improved safety profiles for patients.
How similar studies have gone: Previous research has shown success in developing antibody-drug conjugates, making this approach a promising advancement in cancer treatment.
Where this research is happening
-
Glycot Therapeutics, LLC
Ellicott City, United States Active
Researchers
- Principal investigator: Zong, Guanghui — Glycot Therapeutics, LLC
- Study coordinator: Zong, Guanghui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.